485 related articles for article (PubMed ID: 28835114)
21. Cancer Immunotherapy in Older Patients.
Marrone KA; Forde PM
Cancer J; 2017; 23(4):219-222. PubMed ID: 28731944
[TBL] [Abstract][Full Text] [Related]
22. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
Wilky BA
Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
[TBL] [Abstract][Full Text] [Related]
23. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
24. Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Sweis RF; Luke JJ
Pharmacol Res; 2017 Jun; 120():1-9. PubMed ID: 28323141
[TBL] [Abstract][Full Text] [Related]
25. Inhibitors of the PD-1 Pathway in Tumor Therapy.
LaFleur MW; Muroyama Y; Drake CG; Sharpe AH
J Immunol; 2018 Jan; 200(2):375-383. PubMed ID: 29311378
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales.
Fan L; Li Y; Chen JY; Zheng YF; Xu XM
Cancer Lett; 2019 Aug; 456():23-28. PubMed ID: 30959079
[TBL] [Abstract][Full Text] [Related]
27. Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.
Rotte A; Jin JY; Lemaire V
Ann Oncol; 2018 Jan; 29(1):71-83. PubMed ID: 29069302
[TBL] [Abstract][Full Text] [Related]
28. Acquired resistance to cancer immunotherapy.
Draghi A; Chamberlain CA; Furness A; Donia M
Semin Immunopathol; 2019 Jan; 41(1):31-40. PubMed ID: 29968044
[TBL] [Abstract][Full Text] [Related]
29. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
Gao A; Sun Y; Peng G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
[TBL] [Abstract][Full Text] [Related]
30. Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies.
Allard B; Allard D; Stagg J
Methods Mol Biol; 2016; 1458():159-77. PubMed ID: 27581021
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy in Gynecologic Cancers: Are We There Yet?
Pakish JB; Jazaeri AA
Curr Treat Options Oncol; 2017 Aug; 18(10):59. PubMed ID: 28840453
[TBL] [Abstract][Full Text] [Related]
32. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
[TBL] [Abstract][Full Text] [Related]
33. Recent progress in therapeutic antibodies for cancer immunotherapy.
Lee A; Sun S; Sandler A; Hoang T
Curr Opin Chem Biol; 2018 Jun; 44():56-65. PubMed ID: 29885949
[TBL] [Abstract][Full Text] [Related]
34. Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.
Force J; Leal JHS; McArthur HL
Curr Treat Options Oncol; 2019 Mar; 20(4):35. PubMed ID: 30923913
[TBL] [Abstract][Full Text] [Related]
35. Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
Xie G; Cheng T; Lin J; Zhang L; Zheng J; Liu Y; Xie G; Wang B; Yuan Y
J Immunother Cancer; 2018 Sep; 6(1):88. PubMed ID: 30208943
[TBL] [Abstract][Full Text] [Related]
36. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917
[TBL] [Abstract][Full Text] [Related]
37. Systematic review on the efficacy and safety of immune checkpoint inhibition in renal cell carcinoma.
Lyu C; Li W; Liu S; Gao S; Zhang H; Hao L; Yu H; Wei W; Song J; Yang Y; Wang C; Zhang Z; Wang N
Future Oncol; 2018 Sep; 14(21):2207-2221. PubMed ID: 29726696
[TBL] [Abstract][Full Text] [Related]
38. Selecting immuno-oncology-based drug combinations - what should we be considering?
Festino L; Vanella V; Trojaniello C; Ascierto PA
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):971-985. PubMed ID: 30169990
[TBL] [Abstract][Full Text] [Related]
39. Neoantigens in the immuno-oncology space.
Arlen PM
Future Oncol; 2017 Oct; 13(25):2209-2211. PubMed ID: 28976211
[No Abstract] [Full Text] [Related]
40. Immune signatures predicting responses to immunomodulatory antibody therapy.
Pawelec G
Curr Opin Immunol; 2018 Apr; 51():91-96. PubMed ID: 29550661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
